Cargando…
PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
BACKGROUND: Several lipid guidelines recommend that proprotein convertase subtilisin/kexin type 9 inhibitors should be considered for patients with atherosclerotic cardiovascular disease who are inadequately treated with maximally tolerated lipid-lowering treatment. OBJECTIVES: The PEARL study asses...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702526/ https://www.ncbi.nlm.nih.gov/pubmed/31280466 http://dx.doi.org/10.1007/s40801-019-0158-0 |